BMO Capital analyst Matthew Luchini lowered his price target on Bluebird Bio to $163 after the company's commercial delay in the launch of its Zynteglo in Europe due to the "tightening of manufacturing processes" which, he says, also adds incremental timing risk for the program. The analyst still maintains his Outperform rating on the stock and believes that Bluebird Bio's upcoming data readouts this year will provide investors with "multiple opportunities for upside" in transfusion-dependent beta-thalassemia, or TDT, Sickle Cell Disease, and multiple myeloma.